Description

Technical Parameters

Introduction

peptides

product-1400-1400

Products Description

### Systematic introduction of Survodutide peptide drugs: classification, advantages and physicochemical properties

#### **Introduction**

Survodutide (R&D code: BI 456906) is a new type of peptide drug, jointly developed by Boehringer Ingelheim and Zealand Pharma. As a dual agonist of **GLP-1 (glucagon-like peptide-1) receptor and glucagon (GCG) receptor**, it is mainly used to treat obesity and type 2 diabetes. Its unique dual-target mechanism of action has attracted much attention in the field of metabolic diseases. The following systematically analyzes the characteristics of Survodutide and its related peptide drugs from the perspectives of structural classification, chemical modification, physicochemical properties and formulation characteristics.

---

### **1. Structural classification and mechanism of action**

Based on target selectivity and molecular design, peptide drugs to which Survodutide belongs can be divided into the following categories:

#### **1. Single-target agonists**

- **Typical representatives**: Traditional GLP-1 receptor agonists (such as liraglutide and semaglutide).

- **Structural features**: Contains only GLP-1 analog sequences, and enhances insulin secretion by simulating endogenous GLP-1.

- **Advantages**: Clear hypoglycemic effect and high safety.

- **Limitations**: Limited regulation of body weight and lipid metabolism.

#### **2. Dual-target/multi-target agonists**

- **Representative drugs**: Survodutide, Tirzepatide (GLP-1/GIP dual agonist).

- **Structural features**:

- **Survodutide**: Through molecular engineering, the GLP-1 and glucagon active sequences are integrated into a single peptide chain, and fatty acid side chain modifications are introduced.

- **Mechanism of action**: Simultaneous activation of GLP-1 receptors (promoting insulin secretion and suppressing appetite) and GCG receptors (enhancing energy consumption and promoting lipolysis).

- **Advantages**:

- **Cooperative metabolic regulation**: GLP-1 suppresses appetite, GCG accelerates fat decomposition, and the weight loss effect is significant (clinical trials show a weight loss of more than 15%).

- **Long-term effect**: Fatty acid chain modification prolongs the half-life and supports once-weekly administration.

#### **3. Triple-target agonist (research stage)**

- **Structural features**: Integrate GLP-1, GCG and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist activity.

- **Potential advantages**: Further optimize the balance of glucose and lipid metabolism, but the risk of side effects caused by receptor selectivity needs to be balanced.

---

### **2. Classification and optimization strategy of chemical modification**

The chemical modification of survodutide is crucial to its efficacy and pharmacokinetics, and can be divided into the following categories:

#### **1. Fatty acid side chain modification (Lipidation)**

- **Technical principle**: Covalently link C16-C18 fatty acid chains at specific sites of the peptide chain (such as Lys residues).

- **Representative drugs**: Survodutide, semaglutide.

- **Advantages**:

- **Extended half-life**: Reduce renal clearance by binding to serum albumin, with a half-life of up to 7 days.

- **Enhanced stability**: Resist enzymatic hydrolysis and improve bioavailability of subcutaneous injection.

- **Physical and chemical properties**:

- **Solubility**: The solubility is reduced after modification, and the formulation needs to be optimized (such as buffer pH adjustment).

- **Aggregation tendency**: Micelle formation may occur at high concentrations, and surfactants (such as polysorbate 80) need to be added.

#### **2. PEGylation modification**

- **Technical principle**: Connect polyethylene glycol (PEG) polymer to peptide chain to increase molecular weight.

- **Advantages**:

- **Reduce immunogenicity**: PEG shields peptide epitopes and reduces antibody production.

- **Improve pharmacokinetics**: Prolong circulation time, but may reduce receptor affinity.

- **Limitations**: PEG molecules may cause liver and kidney accumulation toxicity, and clinical application is limited.

#### **3. Amino acid substitution and cyclization**

- **Technical application**:

- **Introduction of non-natural amino acids**: Such as Aib (α-aminoisobutyric acid) to enhance enzyme resistance.

- **Cyclic structure**: Stabilize α-helical conformation through disulfide bonds or chemical cross-linking.

- **Advantages**: Improve metabolic stability and receptor binding specificity.

---

### **3. Analysis of physical and chemical properties**

#### **1. Molecular weight and structure**

- **Survodutide**: Molecular weight is about 4.8 kDa, composed of 39 amino acids, and contains fatty acid side chain modification.

- **Comparison**: The molecular weight of traditional GLP-1 analogs (such as exenatide) is about 4.2 kDa.

#### **2. Solubility and stability**

- **Solubility**:

- **Unmodified peptide**: Easily soluble in water (>50 mg/mL, pH 7.4).

- **Modified peptide**: Fatty acid modification leads to decreased solubility (pH 8.0 buffer or co-solvent is required).

- **Stability**:

- **Temperature sensitivity**: Long-term storage requires 2-8℃ away from light, and lyophilized powder can be stored at room temperature.

- **pH dependence**: Deamidation and hydrolysis are prone to occur under acidic conditions.

#### **3. Color and morphology**

- **API morphology**: White to off-white lyophilized powder (purity>99%).

- **Preparation color**:

- **Solution**: Colorless transparent liquid (stable at pH 7.0-8.5).

- **Suspension**: Milky white (with lipid carrier).

---

### **4. Formulation development and delivery system**

#### **1. Prefilled injection pen**

- **Advantage**: High patient compliance, supporting once-weekly subcutaneous injection.

- **Formulation challenge**: Preservatives (such as phenol) and stabilizers (such as mannitol) need to be added.

#### **2. Long-acting sustained-release microspheres**

- **Technology**: PLGA (polylactic-co-glycolic acid) encapsulates peptide drugs.

- **Advantage**: Extended release to 1 month, reducing injection frequency.

- **Difficulty**: Burst effect and process complexity.

#### **3. Oral peptide preparations (research stage)**

- **Technology**: Enteric coating combined with permeation enhancers (such as SNAC).

- **Challenges**: Low bioavailability (<5%), requiring high dose compensation.

---

### **5. Clinical advantages and market potential**

#### **1. Efficacy advantages**

- **Weight loss effect**: The Survodutide Phase II trial showed an average weight loss of 14.9% in 46 weeks (2.8% in the placebo group).

- **Metabolic improvement**: Significantly reduced liver fat content (>30%) and improved insulin sensitivity.

#### **2. Safety**

- **Common side effects**: Nausea, diarrhea (incidence <20%, mostly transient).

- **Risk control**: Dual-target stimulation did not increase the risk of cardiovascular events.

#### **3. Market prospects**

- **Competitive positioning**: Benchmarking Novo Nordisk's semaglutide and Eli Lilly's Tirzepatide.

- **Differentiation advantage**: Achieve higher energy consumption through GCG receptor activation, suitable for patients with severe obesity.

---

### **6. Future development direction**

1. **Multi-target synergistic design**: Develop GLP-1/GCG/GIP triple agonists to further improve efficacy.

2. **Non-injection dosage form breakthrough**: Promote the development of oral and inhaled preparations.

3. **Personalized treatment**: Screen the best response population through genotyping.

---

### **Conclusion**

Survodutide represents the trend of peptide drugs from single target to multi-target. The combination of its dual receptor agonism mechanism and chemical modification technology significantly improves the therapeutic effect of metabolic diseases. With the advancement of formulation technology and delivery system, such drugs are expected to dominate the fields of obesity and diabetes and provide new ideas for the treatment of other chronic diseases.